Genovate Biotechnology Co., Ltd.

4130

TW0004130000

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-06-11 EDT			5-day change	1st Jan Change
24.3 ^TWD	-1.02%		-0.21%	-8.65%

05-31	Genovate Biotechnology Co., Ltd. Appoints Su, Lai-Shou as a Member of Audit Committee	CI
05-31	Genovate Biotechnology Co., Ltd. Appoints Su, Lau-Shou as Independent Director	CI

Genovate Biotechnology Co., Ltd. Provides Revenue Guidance for the Year 2012

March 29, 2012 at 11:31 am

Genovate Biotechnology Co., Ltd. provided revenue guidance for the year 2012. The company expects with more new products approved in 2011, revenue of Genovate is expected to increase in 2012.

Latest news about Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Co., Ltd. Appoints Su, Lai-Shou as a Member of Audit Committee	05-31	CI
Genovate Biotechnology Co., Ltd. Appoints Su, Lau-Shou as Independent Director	05-31	CI
Genovate Announces Plans to Submit New Drug Application for PMR to the U.S. Food & Drug Administration in the Second Half of 2025	05-28	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	03-28	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Genovate Biotechnology Co., Ltd. Announces Members of the Company's 5th Remuneration Committee	23-08-07	CI
Genovate Biotechnology Co., Ltd. Announces Cash Dividend, Payable August 7, 2023	23-06-15	CI
Genovate Biotechnology Co., Ltd. Approves Election of Directors	23-05-29	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Genovate Biotechnology Co., Ltd. and CSPC Pharmaceutical Group Limited Sign the Agreement on Technology Licensing and Co-Development of DBPR108 in Mainland China	23-04-28	CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Audit Committee Member and Convener of the Remuneration Committee, Effective April 10, 2023	23-04-06	CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Independent Director, Effective April 10, 2023	23-04-06	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-25	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-25	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-24	CI

Chart Genovate Biotechnology Co., Ltd.

Duration

Period

More charts

Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENOVATE BIOTECHNOLOGY CO., LTD.	-8.65%	82.43M
ELI LILLY AND COMPANY	+48.79%	781B
JOHNSON & JOHNSON	-7.23%	350B
MERCK & CO., INC.	+19.43%	330B
ABBVIE INC.	+7.18%	293B
ASTRAZENECA PLC	+17.30%	248B
ROCHE HOLDING AG	+0.08%	221B
NOVARTIS AG	+11.44%	217B
AMGEN INC.	+4.53%	162B
PFIZER, INC.	-3.92%	157B